icon-folder.gif   Conference Reports for NATAP  
 
  65th Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 7-11 2014
Back grey_arrow_rt.gif
 
 
 
Identification and Treatment of Multiple Subtypes of HCV Genotype 4 in the PEARL-I Study With Ombitasvir and ABT-450/r ± Ribavirin
 
 
  Reported by Jules Levin
AASLD Nov 7-11 Boston
 
Gretja Schnell, Rakesh Tripathi, Jill Beyer, Thomas Reisch, Preethi Krishnan, Tolga Baykal, Coleen Hall, Regis A Vilchez, Tami Pilot-Matias, and Christine Collins Research & Development, AbbVie Inc., North Chicago, Illinois, United States
 
AASLD: Interferon-Free Regimens of Ombitasvir and ABT-450/r With or Without Ribavirin in Patients With HCV Genotype 4 Infection: PEARL-I Study Results - (12/01/14)

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif

AASLD10.gif

AASLD11.gif